Tolerance of dinutuximab therapy for treatment of high‐risk neuroblastoma in two patients with end‐stage renal disease on dialysis

Autologous hematopoietic cell transplant (aHCT) has a significant survival advantage in patients with high‐risk (HR) neuroblastoma. Transplant‐associated thrombotic microangiopathy (TA‐TMA) is a serious complication and may result in chronic renal disease leading to delay in subsequent posttransplan...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Pediatric blood & cancer 2021-03, Vol.68 (3), p.e28852-n/a
Hauptverfasser: Emberesh, Myesa, Rubinstein, Jeremy D., Young, Jennifer, Benoit, Stefanie W., Dandoy, Christopher E., Weiss, Brian D.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Autologous hematopoietic cell transplant (aHCT) has a significant survival advantage in patients with high‐risk (HR) neuroblastoma. Transplant‐associated thrombotic microangiopathy (TA‐TMA) is a serious complication and may result in chronic renal disease leading to delay in subsequent posttransplant therapy and limitations of treatment options. Dinutuximab represents an important therapeutic advance in the treatment of pediatric HR neuroblastoma, but historically has not been administered in patients with GFR 
ISSN:1545-5009
1545-5017
DOI:10.1002/pbc.28852